Delivery Order SPE2DB20D3103-SPE2DB26FL5L8
Award Date 11/7/25
Potential Completion Date 11/10/25
Potential Value $1.7K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $5,755.68 to AmerisourceBergen Drug Corp for ACTEMRA ACTPEN 162 MG/0.9 ML auto-injectors. This non-set-aside, firm fixed price delivery order was awarded on July 22, 2025, with an ultimate completion date of July 23, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. ACTEMRA (tocilizumab) is a biologic immunosuppressant used to treat rheumatoid arthritis and other...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,791.56 for ACTEMRA ACTPEN 162 mg/0.9 mL auto-injector pens on August 11, 2025, with performance completion scheduled for August 12, 2025. This firm fixed price delivery order represents a non-set-aside, competitively awarded contract with no small business or other socioeconomic preferences applied. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $49,591.32 delivery order to AmerisourceBergen Drug Corp for the supply of Actemra Actpen (tocilizumab) 162 mg/0.9 mL auto-injector pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance to be completed by September 29, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,808.31 for ACTEMRA ACTPEN 162 MG/0.9 ML (tocilizumab auto-injector pens), a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions. The contract was competitively awarded without a set-aside designation and is structured as a firm fixed price delivery order with an ultimate completion date of October 21, 2025. Performance will take place at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,715.91 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 ml auto-injectors. This firm fixed-price delivery order, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a non-set-aside competitive award. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,382.29 to AmerisourceBergen Drug Corp for Actemra ActPen (tocilizumab) 162 mg/0.9 mL auto-injectors. This firm fixed-price delivery order, issued on November 7, 2025, with completion targeted for November 10, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be...
- The Defense Logistics Agency awarded a $13,292.11 delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Actemra (tocilizumab) Actpen 162 mg/0.9 mL auto-injectors. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility...
- The Defense Logistics Agency awarded a delivery order valued at $14,389.20 to AmerisourceBergen Drug Corp for the supply of Actemra (tocilizumab) Actpen 162 mg/0.9 mL injectable pens. This firm fixed-price delivery order, issued on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a continuation of the company's role as a critical pharmaceutical supplier to the federal government. The contract carries no set-aside designation, indicating it was competitively awarded...
- The Defense Logistics Agency awarded a $2,287.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector units. The contract, which carries an ultimate completion date of October 17, 2025, represents a non-set-aside competitive award with performance to be executed at the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,219.45 to AmerisourceBergen Drug Corp for ACTEMRA ACTPEN 162 mg/0.9 mL auto-injector pens. The contract was competitively awarded without set-aside provisions on May 13, 2025, with an ultimate completion date of May 14, 2025. This delivery order operates under a firm fixed-price arrangement and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. ACTEMRA (tocilizumab) is a biologic...